Announcement on Voluntary Disclosure of Publicity of Furmonertinib Mesilate Tablets for First-line Indication Treatment of EGFR20 Exon Insertion Mutated NSCLC Included in Potential Breakthrough Therapy Variety
· Issued by Shanghai Allist Pharmaceuticals Co. Ltd. Class A via Shanghai Stock Exchange
Announcement on Voluntary Disclosure of Publicity of Furmonertinib Mesilate Tablets for First-line Indication Treatment of EGFR20 Exon Insertion Mutated NSCLC Included in Potential Breakthrough Therapy Variety
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
